MKMailen Konicoff

Mailen Konicoff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mailen Konicoff has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Validation of the Hemodynamic Classification System for Hemodynamic‐Related Events in Patients With Durable Left Ventricular Assist Devices

    by Guglielmo Gallone, Luca Baldetti, Mailen Konicoff, Javier Ibero, Alba Maestro‐Benedicto, Andrew Morley‐Smith, Maria Monteagudo Vela, Francesca Fiorelli, Mark Peterzan, Gemma Edwards, et al.

    Background: Durable left ventricular assist device (dLVAD) physiology predisposes to right heart failure (RHF) and aortic insufficiency (AI), recently labeled hemodynamic‐related events (HDREs). We sought to validate the recently proposed dLVAD Hemodynamic Classification System for HDREs. Methods: RHF and AI HDREs were adjudicated, staged, and phenotyped on the basis of the Hemodynamic Classification System assessed at 6 months after dLVAD implantation. The primary outcome was a composite of HF hospitalization or cardiovascular death between 6 and 24 months after dLVAD implantation. Results: Among 183 qualifying consecutive patients with 6‐month assessments, RHF HDRE was adjudicated in all cases and AI HDRE in 161 (88.0%). Overall, 53 (29.0%) patients developed an RHF HDRE and 26 (16.0%) an AI HDRE (phenotypes: 39 isolated RHF, 15 isolated AI, 11 combined RHF–AI, 3 not adjudicated). At pre‐dLVAD assessment, age and pulmonary artery pulsatility index were independently associated with RHF HDRE and pre‐dLVAD AI and systolic pulmonary artery pressure with AI HDRE. RHF HDRE (adjusted hazard ratio [HR], 2.69 [95% CI, 1.14–6.34]; P =0.024), AI HDRE (adjusted HR, 4.21 [95% CI, 1.70–10.40]; P =0.002), and HDRE phenotypes (isolated RHF/AI HDRE versus no HDRE: adjusted HR, 2.80 [95% CI, 1.03–7.62]; P =0.044; combined RHF/AI HDRE versus no HDRE: adjusted HR, 4.53 [95% CI, 1.33–15.35]; P =0.015) were associated with the primary outcome. A graded increase in primary outcome was observed with increasing RHF and AI stages. Conclusions: We validated the dLVAD Hemodynamic Classification System for HDREs as a valuable tool to identify pathophysiological and clinical clusters of patients, linking it with significant prognostic implications. Its adoption may pave the way for targeted strategies aimed at mitigating HDREs and enhancing the long‐term success of dLVAD support.


  • Open Access

    Increasing the acceptance of thoracoabdominal normothermic regional perfusion in donation after circulatory determination of death heart donation: A case for collaborative donor research

    by John O. Louca, Alex Manara, Ashish Shah, Kelly Schlendorf, Brian Lima, Jacob Schroder, Sarah Casalinova, Carmelo Milano, Kiran Khush, Helen Luikart, et al.


  • Open Access

    Association of Renin‐Angiotensin‐Aldosterone System Inhibitors With Clinical Outcomes, Hemodynamics, and Myocardial Remodeling Among Patients With Advanced Heart Failure on Left Ventricular Assist Device Support

    by Guglielmo Gallone, Javier Ibero, Andrew Morley‐Smith, Maria Monteagudo Vela, Francesca Fiorelli, Mailen Konicoff, Gemma Edwards, Binu Raj, Mayooran Shanmuganathan, Stefano Pidello, et al.

    Background: We evaluated the potential benefits of renin‐angiotensin‐aldosterone system inhibitors (RAASi) in patients with left ventricular assist device support. Methods and Results: A total of 165 consecutive patients undergoing left ventricular assist device implant and alive at 6‐month on support were studied. RAASi status after 6‐month visit along with clinical reasons for nonprescription/uptitration were retrospectively assessed. The primary outcome was a composite of heart failure hospitalization or cardiovascular death between 6 and 24 months after left ventricular assist device implant. Remodeling and hemodynamic outcomes were explored by studying the association of RAASi new prescription/uptitration versus unmodified therapy at 6‐month visit with the change in echocardiographic parameters and hemodynamics between 6 and 18 months. After the 6‐month visit, 76% of patients were on RAASi. Patients' characteristics among those receiving and not receiving RAASi were mostly similar. Of 85 (52%) patients without RAASi new prescription/uptitration at 6‐month visit, 62% had no apparent clinical reason. RAASi were independently associated with the primary outcome (adjusted hazard ratio, 0.31 [95% CI, 0.16–0.69]). The baseline rates of optimal echocardiographic profile (neutral interventricular septum, mitral regurgitation less than mild, and aortic valve opening) and hemodynamic profile (cardiac index ≥2.2 L/min per m 2 , wedge pressure P =0.032) and trends for higher rates of optimal echocardiographic profile (39.6% versus 22.9%; P =0.055) compared with patients with 6‐month unmodified therapy. Optimal 18‐month hemodynamic and echocardiographic profiles were associated with the primary outcome (log‐rank=0.022 and log‐rank=0.035, respectively). Conclusions: RAASi are associated with improved outcomes and improved hemodynamics among mechanically unloaded patients.